Stay updated with breaking news from Alpha Bronze. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Company signs LOI for Nordics and Germany OTTAWA, ON / ACCESSWIRE / February 25, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF), a biopharmaceutical pioneer in immunomodulator
Tetra Bio-Pharma Creates the ENJOUCA Business Unit OTTAWA, ON / ACCESSWIRE / February 3, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF), a biopharmaceutical pioneer in immunomodulator drug discovery and development announced today the creation of a wholly-owned subsidiary called ENJOUCA. Jurisdictions differ greatly in terms of regulatory requirements surrounding medical cannabis, which means that in some territories, QIXLEEF can be commercialized as a medical cannabis product. As a result, Tetra's strategy is to launch QIXLEEF under the trademark, ENJOUCA as ...
Tetra Bio-Pharma Announces FDA Clearance on IND, allowing U.S. Reborn1 Clinical Trial to Commence OTTAWA, ON / ACCESSWIRE / January 29, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development announced today that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application, allowing Tetra to initiate its QIXLEEF TM Reborn1 TM clinical trial in cancer patients with breakthrough pain. "This is really good news for all of us and in particular for the cancer ...
Helix BioPharma Corp.: Helix Biopharma Corp. Responds to Market Activity RICHMOND HILL, ON / ACCESSWIRE / January 13, 2021 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, wishes to confirm that it is not aware of any material, undisclosed information related to the Company that would account for the recent increase in the market price and level of trading volume of its ordinary shares. About Helix BioPharma Corp. Helix Bi...
Tetra Bio-Pharma Files New Drug Submission for REDUVO in Canada Tetra meets another key milestone before the end of the year OTTAWA, ON / ACCESSWIRE / December 30, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development announced today that the New Drug Submission (NDS) for the Dronabinol Soft Gel capsules, has been filed with Health Canada. If successful, it will provide Tetra with its first Drug Identification Number (DIN) for a THC-based prescription drug. The new drug name, REDUVO, is pending approval ...